EP3626270
Meðhöndlun á hjarta- og æðasjúkdómum
Status:
EP einkaleyfi í gildi á ÍslandiEP appl. date:
26.8.2014EP published:
11.10.2023EP application number:
19202854.6
EP translation filed:
8.1.2024Grant published:
15.2.2024EPO information:
European Patent Register
Max expiry date:
25.8.2034Expiry date:
25.8.2026Next due date:
31.8.2026
Title in English:
TREATMENT OF CARDIOVASCULAR DISEASESLanguage of the patent:
English
Timeline
Today
26.8.2014EP application
11.10.2023EP Publication
8.1.2024Translation submitted
15.2.2024Registration published
25.8.2026Expires
Owner
Name:
Novartis AGAddress:
Lichtstrasse 35, 4056 Basel, CH
Inventor
Name:
SHI, Victor ChengweiAddress:
East Hanover, New Jersey 07936, US
Name:
LEFKOWITZ, MartinAddress:
East Hanover, New Jersey 07936, US
Name:
RIZKALA, Adel RemondAddress:
East Hanover, New Jersey 07936, US
Agent
Name:
Árnason Faktor ehf.Address:
Guðríðarstíg 2-4, 113, Reykjavík,
Priority
Number:
PCT/US2013/056680Date:
26.8.2013Country:
WO
Number:
201461972933 PDate:
31.3.2014Country:
US
Classification
Categories:
A61K 45/06, A61K 31/194, A61K 31/197, A61K 31/216, A61K 31/41, A61K 31/221, A61K 31/401, A61K 31/225, A61P 9/12, A61P 9/10
Annual fees
Number
Paid
Expires
Payer
Number: 11
Paid: 23.7.2024
Expires: 25.8.2025
Payer: Árnason Faktor ehf.
Number: 12
Paid: 11.8.2025
Expires: 25.8.2026
Payer: Árnason Faktor ehf.